Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

XLV vs. RYHIX: which is better?

Bottom line

XLV vs RYHIX: the short answer

XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and RYHIX (Health Care Fund) share a meaningful slice of their top holdings — about 79% by weight.

But RYHIX is far broader, holding 135 positions to 65 for XLV, so beyond the top names it adds exposure XLV doesn't have.

XLV is cheaper at 0.08% vs 1.38% — a difference of $130 a year per $10,000 invested.

Over five years, XLV returned +8.1% a year vs +5.1% for RYHIX.

Updated Nov 19, 2026

XLV vs RYHIX side by side

XLVRYHIX
TypeETFMutual fund
Fund familySPDR (State Street)Guggenheim
CategoryHealth Care SectorHealth Care Sector
Expense ratio0.08%1.38%
Annual cost per $10k$8$138
10-yr cost on $10k (prospectus)$103$1,709
Max front loadNone—
12b-1 fee0.02%0%
1-yr return+14.5%+14.4%
5-yr return (annualized)+8.1%+5.1%
10-yr return (annualized)+9.8%+7.9%
Best quarter+14.5%+18.7%
Worst quarter−12.7%−14.4%
Net assets (fund)$40.6B$19.4M
Number of holdings65135
Portfolio turnover2%244%
Returns as ofDec 31, 2025Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearXLVRYHIXDifference
2025+14.5%+14.4%+0.1%
2024+2.5%+0.6%+1.9%
2023+2.0%+5.8%−3.9%
2022−2.1%−11.6%+9.6%
2021+25.9%+19.2%+6.7%
2020+13.3%+18.9%−5.7%
2019+20.7%+22.8%−2.1%
2018+6.3%+1.6%+4.7%
2017+21.7%+23.5%−1.8%
2016−2.8%−9.4%+6.5%

Source: Fund prospectus bar charts

Holdings overlap

23 of XLV's top 25 holdings also appear in RYHIX's top 25.

Shared top holdings
HoldingXLVRYHIX
Eli Lilly & Co16.51%3.63%
Johnson & Johnson10.64%2.88%
AbbVie Inc7.74%2.52%
UnitedHealth Group Inc6.57%2.22%
Merck & Co Inc5.52%2.04%
Amgen Inc3.40%1.56%
Thermo Fisher Scientific Inc3.24%1.61%
Abbott Laboratories2.75%1.42%
Gilead Sciences Inc2.73%1.39%
Intuitive Surgical Inc2.45%1.31%
Pfizer Inc2.39%1.25%
CVS Health Corp2.30%1.31%
Vertex Pharmaceuticals Inc2.19%1.34%
Danaher Corp2.09%1.30%
Bristol-Myers Squibb Co2.05%1.22%

Source: SEC Form N-PORT

XLV top 10

  1. Eli Lilly & Co — 16.51%
  2. Johnson & Johnson — 10.64%
  3. AbbVie Inc — 7.74%
  4. UnitedHealth Group Inc — 6.57%
  5. Merck & Co Inc — 5.52%
  6. Amgen Inc — 3.40%
  7. Thermo Fisher Scientific Inc — 3.24%
  8. Abbott Laboratories — 2.75%
  9. Gilead Sciences Inc — 2.73%
  10. Intuitive Surgical Inc — 2.45%

RYHIX top 10

  1. Eli Lilly & Company — 3.63%
  2. Johnson & Johnson — 2.88%
  3. Abbvie Inc — 2.52%
  4. Unitedhealth Group Inc — 2.22%
  5. Merck & Company Inc — 2.04%
  6. Thermo Fisher Scientific Inc — 1.61%
  7. Amgen Inc — 1.56%
  8. Abbott Laboratories — 1.42%
  9. Gilead Sciences Inc — 1.39%
  10. Vertex Pharmaceuticals Inc — 1.34%

FAQ

What is the difference between XLV and RYHIX?
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and RYHIX (Health Care Fund) share a meaningful slice of their top holdings — about 79% by weight. But RYHIX is far broader, holding 135 positions to 65 for XLV, so beyond the top names it adds exposure XLV doesn't have.
Which is cheaper, XLV or RYHIX?
XLV has the lower expense ratio (0.08%).
Should I own both XLV and RYHIX?
Owning both adds little diversification because their portfolios overlap heavily; most investors pick one.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.